Background: Abnormal cortisol and serotonin concentrations are reported in obese, anxious, and/or depressed individuals. We examined how duodenal levels of these hormones correlated with self-reported anxiety and depression and their individual and combined contribution to weight loss among young metabolic and bariatric surgery (MBS) patients. Methods: Patients <= 30 years of age who had scheduled MBS were recruited. Weight, depression, and anxiety were collected within 2 weeks before MBS, and weight was again collected 6-months post-MBS. Duodenum serotonin and cortisol tissue samples were collected during MBS. Results: The majority of the sample (N = 18, mean age 23.6 years, standard deviation: 4.8 years) was female (72.2%) and Hispanic (66.7%), and 33.3% were non-Hispanic black. Duodenum cortisol (pg/mL) was inversely correlated with the Beck Anxiety Inventory (r = -0.76, p = 0.04) and Beck Depression Inventory (BDI)-II (r = -0.83, p = 0.02). For every pg/mL increase in the amount of (tissue) cortisol plus BDI-II, the score showed a 0.029 pound increase post-MBS (p = 0.02). Conversely, after adjusting for age every unit increase in BDI-II score showed a 1.83 pound decrease post-MBS (p = 0.03). Conclusions: A combined effect of cortisol and depression had a significant effect on weight loss, while depression was independently associated with weight gain. Longitudinal biospecimen collection would add information to these complex relationships.

The trend for improved more precise diagnostics and management of disease heavily relies on the measurement of panels of biomarkers in physiological samples of patients. Ideally, the ultimate goal would be to detect as many clinically relevant biomarkers as possible in a single drop of blood, achieving quick, sensitive, reproducible, and affordable detection in small volume physiological samples. Bioluminescent (BL) proteins provide many of the desired characteristics required for such labels, including detection at extremely low concentrations, no interference from physiological fluids leading to excellent detection limits, and compatibility with many miniaturized systems. However, to date the use of BL proteins has been restricted by their limited multiplexing capabilities. BL proteins typically exhibit a single emission profile and decay kinetics making the simultaneous detection of multiple analytes difficult. Recent progresses in this area include the use of two different engineered luminescent proteins to achieve resolved signals via one-dimensional time resolution. This approach, however, to date only lead to a dual analyte detection. Herein, we have demonstrated that using a two-dimensional approach that combines both temporal and spatial resolution, we can expand the multiplexing capabilities of bioluminescent proteins. To that end, the photoprotein aequorin (AEQ) has been employed for the simultaneous detection of three separate analytes in a single well, differentiated through the use of three discrete time/wavelength windows. Through a combination of site-specific mutations and synthetic coelenterazines "semi-synthetic" AEQ variants have been developed with altered emission profiles and decay kinetics. In this study, two AEQ mutant proteins were genetically conjugated to three pro-inflammatory cytokines (tumor necrosis factor alpha, interleukins 6 and 8) resulting in AEQ-labeled cytokines. These fusion proteins were combined with synthetic coelenterazines resulting in proteins with differing emission maxima and half-lives to allow for the simultaneous detection of all three cytokines in a single sample. The validity of the assay was demonstrated in serum by employing human physiological samples and comparing our results with commercially available individual tests for each of the three cytokines.

There are an estimated 48 million cases of foodborne illness in the United States every year. In general, these illnesses are the result of unintentional contamination and improper food handling. Because bacterial contamination plays a major role in food spoilage and, hence, in foodborne illnesses, it is important to design easy, portable methods to detect bacteria in food. Quorum sensing (QS) enables bacteria to communicate with one another and by doing so they can modulate their behavior in a cell-density dependent manner. In bacteria, quorum sensing molecules (QSMs) are known to control several factors such as virulence factor production, antibiotic production, biofilm formation, and gene regulation. Herein, we demonstrate the applicability of whole cell biosensing systems for the early identification of food contamination via detection of QSMs. Additionally, we have developed a portable system for detection of bacterial contamination using microdots of immobilized whole cell-based biosensors on paper that boast nanomolar level detection of QSMs in two different food matrices, namely beef and milk. Limits of detection ranged from 1 × 10-7 M to 1 × 10-9 M with relative standard deviations (RSDs) of 1-16%. This rapid, easy, and portable test could be a useful tool for use in the field and during all stages of food manipulation, i.e., from farms to distribution, storage, sales, and preparation prior to consumption, to ensure that food is free of bacterial contamination.

We have developed sensing systems employing different classes of transcriptional regulatory proteins genetically and chemically modified to incorporate a fluorescent reporter molecule for detection of arsenic, hydroxylated polychlorinated biphenyls ( OH-PCBs), and cyclic AMP ( cAMP). These are the first examples of optical sensing systems based on transcriptional regulatory proteins.

The increased importance of in vivo diagnostics has posed new demands for imaging technologies. In that regard, there is a need for imaging molecules capable of expanding the applications of current state-of-the-art imaging in vivo diagnostics. To that end, there is a desire for new reporter molecules capable of providing strong signals, are non-toxic, and can be tailored to diagnose or monitor the progression of a number of diseases. Aequorin is a non-toxic photoprotein that can be used as a sensitive marker for bioluminescence in vivo imaging. The sensitivity of aequorin is due to the fact that bioluminescence is a rare phenomenon in nature and, therefore, it does not suffer from autofluorescence, which contributes to background emission. Emission of bioluminescence in the blue-region of the spectrum by aequorin only occurs when calcium, and its luciferin coelenterazine, are bound to the protein and trigger a biochemical reaction that results in light generation. It is this reaction that endows aequorin with unique characteristics, making it ideally suited for a number of applications in bioanalysis and imaging. Herein we report the site-specific incorporation of non-canonical or non-natural amino acids and several coelenterazine analogues, resulting in a catalog of 72 cysteine-free, aequorin variants which expand the potential applications of these photoproteins by providing several red-shifted mutants better suited to use in vivo. In vivo studies in mouse models using the transparent tissue of the eye confirmed the activity of the aequorin variants incorporating L-4-iodophehylalanine and L-4-methoxyphenylalanine after injection into the eye and topical addition of coelenterazine. The signal also remained localized within the eye. This is the first time that aequorin variants incorporating non-canonical amino acids have shown to be active in vivo and useful as reporters in bioluminescence imaging.

Autoinducer-2 (AI-2) is a Quorum Sensing (QS) molecule utilized by bacteria in interspecies communication. More recently, it is identified to be vital in regulating QS pathways in a number of human and foodborne pathogens. Methods to detect AI-2 in a rapid and highly sensitive manner can help in the early detection of bacterial infections. Herein, we describe a rapid, selective, and highly sensitive protein based biosensing system employing the Fluorescence Resonance Energy Transfer (FRET) between a protein fusion LuxP-EGFP and 7-diethylamino-3-[N-(2-maleimidoethyl)carbamoyl]coumarin (MDCC). The developed biosensing system, which can detect AI-2 at subnanomolar levels, was successfully applied to detect AI-2 in clinical samples such as saliva and blood serum.

In recent years, luminescent proteins have been studied for their potential application in a variety of detection systems. Bioluminescent proteins, which do not require an external excitation source, are especially well-suited as reporters in analytical detection. The photoprotein aequorin is a bioluminescent protein that can be engineered for use as a molecular reporter under a wide range of conditions while maintaining its sensitivity. Herein, the characteristics of aequorin as well as the engineering and production of aequorin variants and their impact on signal detection in biological systems are presented. The structural features and activity of aequorin, its benefits as a label for sensing and applications in highly sensitive detection, as well as in gaining insight into biological processes are discussed. Among those, focus has been placed on the highly sensitive calcium detection in vivo, in vitro DNA and small molecule sensing, and development of in vivo imaging technologies.[GRAPHICS].

Advancements in biotechnology have allowed for the preparation of designer proteins with a wide spectrum of unprecedented chemical and physical properties. A variety of chemical and genetic methods can be employed to tailor the protein's properties, including its stability and various functions. Herein, we demonstrate the production of semisynthetic glucose recognition proteins (GRPs) prepared by truncating galactose/glucose binding protein (GBP) of E. coli and expanding the genetic code via global incorporation of unnatural amino acids into the structure of GBP and its fragments. The unnatural amino acids 5,5,5-trifluoroleucine (FL) and 5-fluorotryptophan (FW) were chosen for incorporation into the proteins. The resulting semisynthetic GRPs exhibit enhanced thermal stability and increased detection range of glucose without compromising its binding ability. These modifications enabled the utilization of the protein for the detection of glucose within physiological concentrations (mM) and temperatures ranging from hypothermia to hyperthermia. This ability to endow proteins such as GBP with improved stability and properties is critical in designing the next generation of tailor-made biosensing proteins for continuous in vivo glucose monitoring.

As the importance of blood-glucose control for both diabetic and non-diabetic patients continues to increase, there is a need for more advanced glucose-sensing technologies. In particular, an in vivo glucose sensor is needed that exhibits high accuracy when operating in a continuous manner for a relatively long period of time (3–5 days). Development of such sensors has been hampered, as low accuracy and sensor drift become major problems with in vivo environments, especially for enzyme-based electrochemical glucose sensors. This paper reports on the use of a novel, binding polypeptide-based, fluorescent, glucose-sensing system that promises to overcome many drawbacks of an enzyme-based system while showing the potential for high accuracy, especially at hypoglycemic levels.